Targeting Rare Human PCSK9 Variants for Cholesterol Treatment (2014)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 14/331,665, filed Jul 15, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,999,341 | Targeting Rare Human PCSK9 Variants for Cholesterol Treatment In force · High confidence | Kymab Limited | In force | High confidence | ||
| US 9,034,331 | Targeting Rare Human PCSK9 Variants for Cholesterol Treatment In force · High confidence | Kymab Limited | In force | High confidence | ||
| US 9,034,332 | Precision Medicine by Targeting Rare Human PCSK9 Variants for Cholesterol Treatment In force · High confidence | Kymab Limited | In force | High confidence | ||
| US 9,045,548 | Precision Medicine By Targeting Rare Human PCSK9 Variants for Cholesterol Treatment In force · High confidence | Kymab Limited | In force | High confidence | ||
| US 9,068,012 | Targeting Rare Human PCSK9 Variants for Cholesterol Treatment In force · High confidence | Kymab Limited | In force | High confidence | ||
| US 9,023,359 | Targeting Rare Human PCSK9 Variants for Cholesterol Treatment In force · High confidence | Kymab Limited | In force | High confidence |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.